Iyeon Glycopyrrolate Injection

Adult administration

Administer by intramuscular or intravenous injection; it may be administered undiluted. During anesthesia Preoperative administration: Inject intramuscularly the recommended dose of 0.004 mg (0.02 mL) of glycopyrrolate per kg of body weight, 30-60 minutes before the anticipated time of induction of anesthesia or at the time of preanesthetic medication (narcotics and/or sedatives). Administration during surgery: Administer to prevent vagal reflexes induced by drugs or associated with arrhythmia. Inject 0.1 mg (0.5 mL) intravenously per dose; repeat at 2-3-minute intervals if needed. Determine the number of doses after identifying the cause of the arrhythmia, and take appropriate measures during surgery and anesthesia to correct parasympathetic imbalance. Administration to reverse neuromuscular blockade: Inject 0.2 mg (1 mL) of glycopyrrolate intravenously for every 1.0 mg of neostigmine or 5.0 mg of pyridostigmine. To minimize cardiac adverse effects, the drugs may be mixed and injected intravenously at the same time. Adjunctive treatment of peptic ulcer Inject 0.1 mg (0.5 mL) of glycopyrrolate subcutaneously, intramuscularly, or intravenously per dose, 3-4 times daily at 4-hour intervals. If a stronger effect is required, 0.2 mg (1.0 mL) may be administered.

Child administration

Preoperative administration — 1 month to 12 years of age: Inject 0.004 mg (0.02 mL) per kg of body weight intramuscularly. Preoperative administration — 1 month to 2 years of age: 0.008 mg (0.04 mL) per kg of body weight may be administered. Administration during surgery — Children: Inject 0.004 mg (0.02 mL) per kg of body weight intravenously; do not exceed a single dose of 0.1 mg (0.5 mL). If repeated, administer at 2-3-minute intervals. Administration to reverse neuromuscular blockade — Children: Inject 0.2 mg (1 mL) of glycopyrrolate intravenously for every 1.0 mg of neostigmine or 5.0 mg of pyridostigmine. To minimize cardiac adverse effects, the drugs may be mixed and injected intravenously at the same time.

This medication contains benzyl alcohol and should not be administered to premature infants or neonates, as it can cause life-threatening respiratory problems. When using the ampule, care must be taken during cutting due to the potential for glass fragments to mix in, especially when administering to children and the elderly. Do not use this drug in individuals with allergies to it or in cases involving neonates and premature infants. When using it as an adjunct for peptic ulcer treatment, it should not be administered in cases of glaucoma, obstructive uropathy, obstructive gastrointestinal disorders, paralytic ileus, intestinal hypotonia in the elderly and frail, unstable cardiovascular conditions due to acute bleeding, severe ulcerative colitis, myasthenia gravis, megacolon patients, and children under 12 years old. Caution should be exercised in administering it to pregnant or lactating women, patients with coronary artery disease, congestive heart failure, arrhythmia, hypertension, hyperthyroidism, asthma, glaucoma, the elderly, autonomic nervous diseases, liver or kidney disease, ulcerative colitis, and patients with hiatal hernia. This medication may cause dry mouth, urinary disorders, urinary retention, blurred vision due to mydriasis, increased intraocular pressure, tachycardia, palpitations, decreased sweating, taste disturbances, headaches, nervousness, drowsiness, fatigue, dizziness, insomnia, nausea, vomiting, erectile dysfunction, decreased milk secretion, constipation, swelling, severe allergic reactions, hives, and confusion or agitation in the elderly. Administering this drug in hot environments may reduce sweating and lead to heatstroke; therefore, caution is required, and drug withdrawal should be considered in patients after intestinal surgery if severe diarrhea occurs due to a potential risk of intestinal obstruction. Additionally, this medication can cause drowsiness or visual impairment, so driving or operating hazardous machinery should be avoided. In cases of overdose, neuromuscular blocking symptoms may occur, requiring professional treatment, and specific antidotes can be used to manage the anticholinergic effects. This medication can be mixed with various injection solutions, but it is safest not to mix it with solutions having a pH above 6. During anesthesia, there is a risk of ventricular arrhythmias, so the injection speed and dosage must be adjusted and administered carefully.

• dry mouth
• urinary disorders
• urinary retention
• blurred vision due to mydriasis
• increased intraocular pressure
• tachycardia
• palpitations
• decreased sweating
• loss of taste
• headache

This medication should be stored in a sealed container to protect it from exposure to air, with a storage temperature maintained between 1 degree and 30 degrees Celsius. By keeping it this way, the medication's efficacy can be well maintained, preventing degradation.

Appearance

Colorless and transparent injection solution filled in an ampule or vial

Package unit

1mL/ampule × 50